Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
JP Morgan 2022 – Abbvie looks to crack the cystic fibrosis code
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.
JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry
But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.
JP Morgan 2022 roundup – Biogen in focus
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
